News
BDTX
1.595
-14.25%
-0.265
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Black Diamond Therapeutics (BDTX) and CalciMedica (CALC)
TipRanks · 13h ago
Why Is Black Diamond Therapeutics Stock Soaring Tuesday?
Benzinga · 16h ago
Black Diamond Therapeutics’ silevertinib shows efficacy in Phase 2 trial
TipRanks · 17h ago
Black Diamond Therapeutics GAAP EPS of -$0.17
Seeking Alpha · 19h ago
Black Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares Rise
NASDAQ · 22h ago
Black Diamond Therapeutics Reports Updated Phase 2 Silevertinib Data, FDA End-Of-Phase 2 Feedback, Supporting Pivotal Development In All 1L EGFR-NCM NSCLC Patients With Potential For Accelerated Approval Based On CNS-ORR
Benzinga · 23h ago
*Black Diamond Theraptcs 3Q Loss/Shr 17c >BDTX
Dow Jones · 23h ago
Press Release: Black Diamond Therapeutics -2-
Dow Jones · 23h ago
*Black Diamond Therapeutics: FDA Feedback Supports Clear Path to Potential Registration in 1L EGFR-NCM NSCLC
Dow Jones · 23h ago
*Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results
Dow Jones · 23h ago
Press Release: Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
Dow Jones · 23h ago
Black Diamond: Q3 Earnings Snapshot
Barchart · 1d ago
Black Diamond Therapeutics To Host A Webcast For Investors To Present Updated Results From Its Ongoing Phase 2 Trial Of Silevertinib
Benzinga · 1d ago
Weekly Report: what happened at BDTX last week (1102-1106)?
Weekly Report · 2d ago
Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy
Seeking Alpha · 11/03 16:50
Weekly Report: what happened at BDTX last week (1026-1030)?
Weekly Report · 11/02 09:27
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
Analysts Offer Insights on Healthcare Companies: Centene (CNC), Aclaris Therapeutics (ACRS) and Black Diamond Therapeutics (BDTX)
TipRanks · 10/29 11:20
Black Diamond Theraptcs Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 10/29 10:55
HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
Benzinga · 10/29 10:45
More
Webull provides a variety of real-time BDTX stock news. You can receive the latest news about Black Diamond Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.